You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorpropamide
Accession NumberDB00672  (APRD00029)
TypeSmall Molecule
GroupsApproved
DescriptionChlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Structure
Thumb
Synonyms
1-(P-Chlorobenzenesulfonyl)-3-propylurea
1-(P-Chlorophenylsulfonyl)-3-propylurea
1-Propyl-3-(P-chlorobenzenesulfonyl)urea
4-chloro-N-((Propylamino)carbonyl)benzenesulfonamide
4-chloro-N-[(Propylamino)carbonyl]benzenesulfonamide
Chlorpropamid
Chlorpropamide
Chlorpropamidum
Clorpropamida
N-(4-Chlorophenylsulfonyl)-n'-propylurea
N-(P-Chlorobenzenesulfonyl)-n'-propylurea
N-Propyl-n'-(P-chlorobenzenesulfonyl)urea
N-Propyl-n'-P-chlorophenylsulfonylcarbamide
External Identifiers
  • Hoechst 18810
  • P 607
  • U 9818
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorpropamide 100 Tab USPtablet100 mgoralPro Doc Limitee1983-12-312009-07-23Canada
Chlorpropamide Tab 250mgtablet250 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Chlorpropamide Tab 250mgtablet250 mgoralPro Doc Limitee1969-12-312009-07-23Canada
Diabinese Tab 100mgtablet100 mgoralPfizer Canada Inc1958-12-312000-10-18Canada
Diabinese Tab 250mgtablet250 mgoralPfizer Canada Inc1958-12-312000-07-26Canada
Novo-propamide 250mgtablet250 mgoralNovopharm Limited1969-12-312010-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorpropamide Tab 100mgtablet100 mgoralApotex Inc1977-12-31Not applicableCanada
Apo Chlorpropamide Tab 250mgtablet250 mgoralApotex Inc1974-12-31Not applicableCanada
Chlorpropamidetablet100 mg/1oralMylan Pharmaceuticals Inc.1984-06-01Not applicableUs
Chlorpropamidetablet250 mg/1oralMylan Pharmaceuticals Inc.1984-06-01Not applicableUs
Chlorpropamidetablet250 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbemideKobayashi Kako
ChloronaseHoechst
DabinesePfizer
DiabeedolSriprasit Dispensary
DiabemideGuidotti
DiabezinPrince
DiabinesePfizer
DiabitexPlantex-Ikapharm
DibeconPharmasant
GlyceminSiam Bheasach
HypomideAspen Pharmacare
LitangenMing Ta
PropamideAtlantic
TraneOmega
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIWTM2C3IL2X
CAS number94-20-2
WeightAverage: 276.74
Monoisotopic: 276.033540689
Chemical FormulaC10H13ClN2O3S
InChI KeyInChIKey=RKWGIWYCVPQPMF-UHFFFAOYSA-N
InChI
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
IUPAC Name
1-(4-chlorobenzenesulfonyl)-3-propylurea
SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Sulfonylurea
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of NIDDM in conjunction with diet and exercise.
PharmacodynamicsChlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide.
Mechanism of actionSulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
Related Articles
AbsorptionReadily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration.
Volume of distributionNot Available
Protein bindingHighly bound to plasma proteins.
Metabolism

Up to 80% of dose is metabolized likely through the liver to to 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced by decomposition in urine. It is unknown whether chlorpropamide metabolites exert hypoglycemic effects.

SubstrateEnzymesProduct
Chlorpropamide
2-HydroxychlorpropamideDetails
Chlorpropamide
Not Available
3-HydroxychlorpropamideDetails
Chlorpropamide
Not Available
p-Chlorobenzene sulfonylureaDetails
p-Chlorobenzene sulfonylurea
Not Available
p-Chlorobenzene sulfonamideDetails
Route of elimination80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours.
Half lifeApproximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.
ClearanceNot Available
ToxicityIPN-RAT LD50 580 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.8087
Caco-2 permeable-0.6198
P-glycoprotein substrateNon-substrate0.6087
P-glycoprotein inhibitor INon-inhibitor0.9009
P-glycoprotein inhibitor IINon-inhibitor0.9533
Renal organic cation transporterNon-inhibitor0.8747
CYP450 2C9 substrateSubstrate0.5553
CYP450 2D6 substrateNon-substrate0.8806
CYP450 3A4 substrateNon-substrate0.7042
CYP450 1A2 substrateNon-inhibitor0.9044
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9592
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6454
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7685
BiodegradationNot ready biodegradable0.9206
Rat acute toxicity2.1413 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9072
hERG inhibition (predictor II)Non-inhibitor0.9306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Watson laboratories inc
  • Pfizer laboratories div pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral250 mg
Tabletoral100 mg/1
Tabletoral250 mg/1
Prices
Unit descriptionCostUnit
Diabinese 250 mg tablet1.34USD tablet
Diabinese 100 mg tablet0.61USD tablet
Chlorpropamide 250 mg tablet0.46USD tablet
Chlorpropamide 100 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129.2-129.8McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc.
water solubility258 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.27HANSCH,C ET AL. (1995)
logS-3.03ADME Research, USCD
pKa5.13LIPINSKI,CA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.157 mg/mLALOGPS
logP2.15ALOGPS
logP1.94ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity65.43 m3·mol-1ChemAxon
Polarizability27.06 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co.,
Inc.

General ReferencesNot Available
External Links
ATC CodesA10BB02
AHFS Codes
  • 68:20.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (35.8 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Chlorpropamide.
AbirateroneThe metabolism of Chlorpropamide can be decreased when combined with Abiraterone.
AcarboseAcarbose may increase the hypoglycemic activities of Chlorpropamide.
AcebutololAcebutolol may increase the hypoglycemic activities of Chlorpropamide.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chlorpropamide.
AcenocoumarolChlorpropamide may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorpropamide.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Chlorpropamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Chlorpropamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorpropamide.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpropamide.
AicarAicar may increase the hypoglycemic activities of Chlorpropamide.
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Chlorpropamide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chlorpropamide.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorpropamide.
AllopurinolThe serum concentration of Chlorpropamide can be increased when it is combined with Allopurinol.
AlogliptinAlogliptin may increase the hypoglycemic activities of Chlorpropamide.
AlprenololAlprenolol may increase the hypoglycemic activities of Chlorpropamide.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorpropamide.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Chlorpropamide.
AmiodaroneThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpropamide.
Ammonium chlorideThe serum concentration of Chlorpropamide can be increased when it is combined with Ammonium chloride.
AmoxapineAmoxapine may increase the hypoglycemic activities of Chlorpropamide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorpropamide.
AprepitantThe metabolism of Chlorpropamide can be increased when combined with Aprepitant.
AripiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.
ArmodafinilThe metabolism of Chlorpropamide can be decreased when combined with Armodafinil.
ArotinololArotinolol may increase the hypoglycemic activities of Chlorpropamide.
Arsenic trioxideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Arsenic trioxide.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorpropamide.
ArticaineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chlorpropamide.
AtenololAtenolol may increase the hypoglycemic activities of Chlorpropamide.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chlorpropamide.
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorpropamide.
BefunololBefunolol may increase the hypoglycemic activities of Chlorpropamide.
BendroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Chlorpropamide.
BetamethasoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Betamethasone.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorpropamide.
BetaxololBetaxolol may increase the hypoglycemic activities of Chlorpropamide.
BevantololBevantolol may increase the hypoglycemic activities of Chlorpropamide.
BezafibrateBezafibrate may increase the hypoglycemic activities of Chlorpropamide.
BisoprololBisoprolol may increase the hypoglycemic activities of Chlorpropamide.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chlorpropamide.
BopindololBopindolol may increase the hypoglycemic activities of Chlorpropamide.
BortezomibThe metabolism of Chlorpropamide can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpropamide.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.
BrexpiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Brexpiprazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpropamide.
BuforminBuformin may increase the hypoglycemic activities of Chlorpropamide.
BufuralolBufuralol may increase the hypoglycemic activities of Chlorpropamide.
BumetanideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.
BupranololBupranolol may increase the hypoglycemic activities of Chlorpropamide.
BuserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Buserelin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpropamide.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorpropamide.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorpropamide.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpropamide.
CapecitabineThe metabolism of Chlorpropamide can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Chlorpropamide.
CarbamazepineThe metabolism of Chlorpropamide can be increased when combined with Carbamazepine.
CarbocisteineThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Carbocisteine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorpropamide.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Chlorpropamide.
CarteololCarteolol may increase the hypoglycemic activities of Chlorpropamide.
CarvedilolCarvedilol may increase the hypoglycemic activities of Chlorpropamide.
CastanospermineCastanospermine may increase the hypoglycemic activities of Chlorpropamide.
CeliprololCeliprolol may increase the hypoglycemic activities of Chlorpropamide.
CeritinibThe serum concentration of Chlorpropamide can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorpropamide.
ChloramphenicolThe metabolism of Chlorpropamide can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorthalidone.
CholecalciferolThe metabolism of Chlorpropamide can be decreased when combined with Cholecalciferol.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Chlorpropamide.
CimetidineThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Chlorpropamide.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chlorpropamide.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorpropamide.
CitalopramCitalopram may increase the hypoglycemic activities of Chlorpropamide.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Chlorpropamide.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Chlorpropamide.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorpropamide.
ClofibrateClofibrate may increase the hypoglycemic activities of Chlorpropamide.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorpropamide.
ClomipramineClomipramine may increase the hypoglycemic activities of Chlorpropamide.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorpropamide.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpropamide.
ClotrimazoleThe metabolism of Chlorpropamide can be decreased when combined with Clotrimazole.
ClozapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Clozapine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chlorpropamide.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorpropamide.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorpropamide.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpropamide.
CorticotropinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cortisone acetate.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chlorpropamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpropamide.
CyclosporineThe metabolism of Chlorpropamide can be decreased when combined with Cyclosporine.
Cyproterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorpropamide.
DabrafenibThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Chlorpropamide.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorpropamide.
DanazolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Danazol.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpropamide.
DapoxetineDapoxetine may increase the hypoglycemic activities of Chlorpropamide.
DarunavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Chlorpropamide.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Chlorpropamide.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpropamide.
DelavirdineThe metabolism of Chlorpropamide can be decreased when combined with Delavirdine.
DesogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpropamide.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorpropamide.
DiazoxideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Diazoxide.
DicoumarolChlorpropamide may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dienogest.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpropamide.
DiflunisalDiflunisal may increase the hypoglycemic activities of Chlorpropamide.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorpropamide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chlorpropamide.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Chlorpropamide.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpropamide.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chlorpropamide.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chlorpropamide.
DisopyramideChlorpropamide may increase the hypoglycemic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorpropamide.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Chlorpropamide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpropamide.
DrospirenoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.
DulaglutideDulaglutide may increase the hypoglycemic activities of Chlorpropamide.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpropamide.
EfavirenzThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorpropamide.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorpropamide.
EpinephrineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Epinephrine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorpropamide.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chlorpropamide.
EscitalopramEscitalopram may increase the hypoglycemic activities of Chlorpropamide.
Eslicarbazepine acetateThe metabolism of Chlorpropamide can be decreased when combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the hypoglycemic activities of Chlorpropamide.
EsomeprazoleThe metabolism of Chlorpropamide can be decreased when combined with Esomeprazole.
EstradiolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estradiol.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorpropamide.
EstriolThe serum concentration of Estriol can be increased when it is combined with Chlorpropamide.
EstroneThe serum concentration of Estrone can be increased when it is combined with Chlorpropamide.
Estrone sulfateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethinyl Estradiol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpropamide.
Ethyl biscoumacetateChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethynodiol diacetate.
EtofibrateEtofibrate may increase the hypoglycemic activities of Chlorpropamide.
EtonogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Chlorpropamide.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chlorpropamide.
EtravirineThe metabolism of Chlorpropamide can be decreased when combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorpropamide.
EverolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Chlorpropamide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorpropamide.
FenfluramineFenfluramine may increase the hypoglycemic activities of Chlorpropamide.
FenofibrateFenofibrate may increase the hypoglycemic activities of Chlorpropamide.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Chlorpropamide.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorpropamide.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorpropamide.
FloxuridineThe metabolism of Chlorpropamide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Chlorpropamide can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.
FluorouracilThe metabolism of Chlorpropamide can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Chlorpropamide.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Chlorpropamide.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpropamide.
FluvastatinThe metabolism of Chlorpropamide can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Chlorpropamide.
FosamprenavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fosamprenavir.
FosphenytoinThe metabolism of Chlorpropamide can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Chlorpropamide.
FurosemideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorpropamide.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpropamide.
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Chlorpropamide.
GlibornurideGlibornuride may increase the hypoglycemic activities of Chlorpropamide.
GliclazideChlorpropamide may increase the hypoglycemic activities of Gliclazide.
GlimepirideGlimepiride may increase the hypoglycemic activities of Chlorpropamide.
GlipizideChlorpropamide may increase the hypoglycemic activities of Glipizide.
GliquidoneGliquidone may increase the hypoglycemic activities of Chlorpropamide.
GlyburideChlorpropamide may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorpropamide.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpropamide.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Chlorpropamide.
HexamethylenetetramineThe serum concentration of Chlorpropamide can be increased when it is combined with Hexamethylenetetramine.
HistrelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Chlorpropamide.
HydrochlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorpropamide.
HydroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroxyprogesterone caproate.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorpropamide.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Chlorpropamide.
IloperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chlorpropamide.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chlorpropamide.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chlorpropamide.
IndalpineIndalpine may increase the hypoglycemic activities of Chlorpropamide.
IndapamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.
IndenololIndenolol may increase the hypoglycemic activities of Chlorpropamide.
IndinavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chlorpropamide.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorpropamide.
Insulin AspartChlorpropamide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirChlorpropamide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Chlorpropamide.
Insulin GlulisineChlorpropamide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanChlorpropamide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Chlorpropamide.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Chlorpropamide.
IproclozideIproclozide may increase the hypoglycemic activities of Chlorpropamide.
IproniazidIproniazid may increase the hypoglycemic activities of Chlorpropamide.
IrbesartanThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorpropamide.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.
IsoniazidThe metabolism of Chlorpropamide can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorpropamide.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorpropamide.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chlorpropamide.
KetoconazoleThe metabolism of Chlorpropamide can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the hypoglycemic activities of Chlorpropamide.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorpropamide.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpropamide.
LanreotideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lanreotide.
LanreotideChlorpropamide may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpropamide.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpropamide.
LeflunomideThe metabolism of Chlorpropamide can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpropamide.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chlorpropamide.
LeuprolideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpropamide.
LevobunololLevobunolol may increase the hypoglycemic activities of Chlorpropamide.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chlorpropamide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Chlorpropamide.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpropamide.
LevonorgestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Levonorgestrel.
LinagliptinLinagliptin may increase the hypoglycemic activities of Chlorpropamide.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chlorpropamide.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Chlorpropamide.
LiraglutideLiraglutide may increase the hypoglycemic activities of Chlorpropamide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorpropamide.
LopinavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorpropamide.
LosartanThe metabolism of Chlorpropamide can be decreased when combined with Losartan.
LovastatinThe metabolism of Chlorpropamide can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Chlorpropamide.
LuliconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Chlorpropamide can be decreased when it is combined with Lumacaftor.
LurasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorpropamide.
MebanazineMebanazine may increase the hypoglycemic activities of Chlorpropamide.
MecaserminChlorpropamide may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Megestrol acetate.
MesalazineMesalazine may increase the hypoglycemic activities of Chlorpropamide.
MestranolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Mestranol.
MetforminMetformin may increase the hypoglycemic activities of Chlorpropamide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorpropamide.
MethotrimeprazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Chlorpropamide.
MethylprednisoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methylprednisolone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Chlorpropamide.
MetipranololMetipranolol may increase the hypoglycemic activities of Chlorpropamide.
MetolazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.
MetoprololMetoprolol may increase the hypoglycemic activities of Chlorpropamide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorpropamide.
MetreleptinMetreleptin may increase the hypoglycemic activities of Chlorpropamide.
MiconazoleMiconazole may increase the hypoglycemic activities of Chlorpropamide.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.
MifepristoneChlorpropamide may increase the hypoglycemic activities of Mifepristone.
MiglitolMiglitol may increase the hypoglycemic activities of Chlorpropamide.
MiglustatMiglustat may increase the hypoglycemic activities of Chlorpropamide.
MilnacipranMilnacipran may increase the hypoglycemic activities of Chlorpropamide.
MinaprineMinaprine may increase the hypoglycemic activities of Chlorpropamide.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chlorpropamide.
MitiglinideMitiglinide may increase the hypoglycemic activities of Chlorpropamide.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorpropamide.
MoclobemideMoclobemide may increase the hypoglycemic activities of Chlorpropamide.
ModafinilThe metabolism of Chlorpropamide can be decreased when combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Chlorpropamide.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpropamide.
NadololNadolol may increase the hypoglycemic activities of Chlorpropamide.
NadololThe serum concentration of Nadolol can be increased when it is combined with Chlorpropamide.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpropamide.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorpropamide.
NateglinideChlorpropamide may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chlorpropamide.
NiacinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Chlorpropamide.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Chlorpropamide.
NicardipineThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chlorpropamide.
NilotinibThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Chlorpropamide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorpropamide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpropamide.
NorethisteroneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Chlorpropamide.
OctreotideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Octreotide.
OctreotideChlorpropamide may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Chlorpropamide.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Chlorpropamide.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpropamide.
OmeprazoleThe metabolism of Chlorpropamide can be decreased when combined with Omeprazole.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Chlorpropamide.
OxandroloneOxandrolone may increase the hypoglycemic activities of Chlorpropamide.
OxprenololOxprenolol may increase the hypoglycemic activities of Chlorpropamide.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Chlorpropamide.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chlorpropamide.
PaliperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chlorpropamide.
PantoprazoleThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.
PargylinePargyline may increase the hypoglycemic activities of Chlorpropamide.
ParoxetineParoxetine may increase the hypoglycemic activities of Chlorpropamide.
PasireotideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pasireotide.
PasireotideChlorpropamide may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Chlorpropamide.
PenbutololPenbutolol may increase the hypoglycemic activities of Chlorpropamide.
PentamidineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pentamidine.
PentamidineChlorpropamide may increase the hypoglycemic activities of Pentamidine.
PhenelzinePhenelzine may increase the hypoglycemic activities of Chlorpropamide.
PhenforminPhenformin may increase the hypoglycemic activities of Chlorpropamide.
PhenindioneChlorpropamide may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Chlorpropamide.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Chlorpropamide.
PhenobarbitalThe metabolism of Chlorpropamide can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Chlorpropamide.
PhenprocoumonChlorpropamide may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorpropamide.
PhenytoinThe metabolism of Chlorpropamide can be increased when combined with Phenytoin.
PindololPindolol may increase the hypoglycemic activities of Chlorpropamide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Chlorpropamide.
PiperazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Chlorpropamide.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorpropamide.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Chlorpropamide.
PolythiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpropamide.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorpropamide.
PractololPractolol may increase the hypoglycemic activities of Chlorpropamide.
PramlintidePramlintide may increase the hypoglycemic activities of Chlorpropamide.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorpropamide.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chlorpropamide.
PrednisoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorpropamide.
PrednisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorpropamide.
PrimidoneThe metabolism of Chlorpropamide can be increased when combined with Primidone.
ProbenecidThe protein binding of Chlorpropamide can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chlorpropamide.
PropranololPropranolol may increase the hypoglycemic activities of Chlorpropamide.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chlorpropamide.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpropamide.
PyrimethamineThe metabolism of Chlorpropamide can be decreased when combined with Pyrimethamine.
QuetiapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quetiapine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Chlorpropamide.
QuinethazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Chlorpropamide.
QuinineChlorpropamide may increase the hypoglycemic activities of Quinine.
RanitidineThe serum concentration of Chlorpropamide can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpropamide.
RasagilineRasagiline may increase the hypoglycemic activities of Chlorpropamide.
RepaglinideChlorpropamide may increase the hypoglycemic activities of Repaglinide.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chlorpropamide.
RifampicinThe serum concentration of Chlorpropamide can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Chlorpropamide.
RifapentineThe metabolism of Chlorpropamide can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpropamide.
RisperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Risperidone.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chlorpropamide.
RitonavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chlorpropamide.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpropamide.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorpropamide.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Chlorpropamide.
SafrazineSafrazine may increase the hypoglycemic activities of Chlorpropamide.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Chlorpropamide.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorpropamide.
SaquinavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chlorpropamide.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Chlorpropamide.
SecobarbitalThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Chlorpropamide.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorpropamide.
SertralineSertraline may increase the hypoglycemic activities of Chlorpropamide.
SildenafilThe metabolism of Chlorpropamide can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Chlorpropamide.
SirolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Chlorpropamide.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chlorpropamide.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorpropamide.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chlorpropamide.
SorafenibThe metabolism of Chlorpropamide can be decreased when combined with Sorafenib.
SotalolSotalol may increase the hypoglycemic activities of Chlorpropamide.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpropamide.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorpropamide.
StanozololStanozolol may increase the hypoglycemic activities of Chlorpropamide.
StiripentolThe metabolism of Chlorpropamide can be decreased when combined with Stiripentol.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Chlorpropamide.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Chlorpropamide.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Chlorpropamide.
SulodexideSulodexide may increase the hypoglycemic activities of Chlorpropamide.
SunitinibChlorpropamide may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chlorpropamide.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chlorpropamide.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpropamide.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorpropamide.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chlorpropamide.
TemsirolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Temsirolimus.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpropamide.
TestosteroneTestosterone may increase the hypoglycemic activities of Chlorpropamide.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpropamide.
TicagrelorThe metabolism of Chlorpropamide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Chlorpropamide can be decreased when combined with Ticlopidine.
TimololTimolol may increase the hypoglycemic activities of Chlorpropamide.
TimololThe serum concentration of Timolol can be increased when it is combined with Chlorpropamide.
TipranavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.
TolazamideChlorpropamide may increase the hypoglycemic activities of Tolazamide.
TolbutamideChlorpropamide may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Chlorpropamide.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorpropamide.
TopiramateThe metabolism of Chlorpropamide can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpropamide.
TorasemideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Chlorpropamide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Chlorpropamide.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorpropamide.
TrazodoneTrazodone may increase the hypoglycemic activities of Chlorpropamide.
TriamcinoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.
TrimethoprimThe metabolism of Chlorpropamide can be decreased when combined with Trimethoprim.
TriptorelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Chlorpropamide.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorpropamide.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorpropamide.
Valproic AcidThe metabolism of Chlorpropamide can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorpropamide.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chlorpropamide.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chlorpropamide.
VilazodoneVilazodone may increase the hypoglycemic activities of Chlorpropamide.
VildagliptinVildagliptin may increase the hypoglycemic activities of Chlorpropamide.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chlorpropamide.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorpropamide.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorpropamide.
VogliboseVoglibose may increase the hypoglycemic activities of Chlorpropamide.
VoriconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Voriconazole.
VorinostatThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Chlorpropamide.
WarfarinChlorpropamide may increase the anticoagulant activities of Warfarin.
ZafirlukastThe metabolism of Chlorpropamide can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpropamide.
ZimelidineZimelidine may increase the hypoglycemic activities of Chlorpropamide.
ZiprasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Food reduces the rate of absorption.
  • Take 30 minutes before meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular Weight:
176990.36 Da
References
  1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74. [PubMed:18220763 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23